Panbela Therapeutics (OTCMKTS:PBLA – Get Free Report) is expected to be announcing its resultson Wednesday, August 12th. Analysts expect Panbela Therapeutics to post earnings of ($2,640.00) per share for the quarter.
Panbela Therapeutics Stock Performance
Shares of PBLA opened at $0.01 on Wednesday. Panbela Therapeutics has a one year low of $0.00 and a one year high of $0.17. The stock’s fifty day moving average is $0.01 and its 200-day moving average is $0.01. The firm has a market capitalization of $53,835.00, a price-to-earnings ratio of -0.00 and a beta of 42.81.
Panbela Therapeutics Company Profile
Panbela Therapeutics, Inc (NASDAQ: PBLA) is a clinical‐stage biotechnology company focused on developing first‐in‐class therapies that modulate polyamine metabolism to treat aggressive cancers. The company’s lead investigational compound, SBP-101, is a proprietary stabilized spermine analogue designed to induce tumor cell apoptosis by dysregulating polyamine levels. Panbela has centered its pipeline largely on SBP-101 in combination with standard‐of‐care regimens for high‐mortality indications such as metastatic pancreatic adenocarcinoma and high‐risk myelodysplastic syndromes (HR-MDS).
In its pancreatic cancer program, Panbela is evaluating SBP-101 alongside gemcitabine and nab-paclitaxel in a Phase 1b/2 study, with interim data having been presented at major oncology conferences.
Featured Stories
- Five stocks we like better than Panbela Therapeutics
- Caterpillar’s Record Quarter May Have Reset the Stock’s Ceiling
- The Real Reason Amazon Hit a $3 Trillion Valuation
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
